Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells

Hiroyuki Otani, Fumio Otsuka, Kenichi Inagaki, Jiro Suzuki, Hirofumi Makino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aldosterone production occurs in the adrenal cortex, and is regulated primarily by angiotensin II (Ang II), potassium and adrenocorticotropin (ACTH). In the presence of the aldosterone stimulators, steroidogenesis is further governed by local autocrine and/or paracrine factors in the adrenal cortex. We reported the presence of functional bone morphogenetic protein (BMP) system in the adrenal cortex and also demonstrated that BMP-6 increases Ang Il-induced aldosterone production, which could be involved in the "aldosterone breakthrough" phenomenon. Aldosterone breakthrough is the phenomenon by which circulating aldosterone concentrations increase above pre-treatment levels after long-term therapy with ACE inhibitors or Ang II type 1 receptor antagonists (ARB). This phenomenon may lead to important clinical consequences since increased aldosterone in a high-salt state facilitates cardiovascular and renal damage in hypertensive patients. We found that long-term ARB treatment reverses the reduction of aldosterone synthesis by adrenocortical cells, thereby causing "cellular aldosterone breakthrough". The availability of BMP-6 in the adrenal cortex may be at least partly involved in the occurrence of cellular escape from aldosterone suppression under chronic treatment with ARB.

Original languageEnglish
Pages (from-to)213-218
Number of pages6
JournalActa Medica Okayama
Volume64
Issue number4
Publication statusPublished - Aug 2010

Fingerprint

Bone Morphogenetic Protein 6
Aldosterone
Adrenal Cortex
Adrenocorticotropic Hormone
Angiotensin II Type 1 Receptor Blockers
Bone Morphogenetic Proteins
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Potassium

Keywords

  • Adrenal cortex
  • Aldosterone
  • Angiotensin II
  • Bone morphogenetic protein

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells. / Otani, Hiroyuki; Otsuka, Fumio; Inagaki, Kenichi; Suzuki, Jiro; Makino, Hirofumi.

In: Acta Medica Okayama, Vol. 64, No. 4, 08.2010, p. 213-218.

Research output: Contribution to journalArticle

@article{3cea2fe996bd4eceb5cfbbb4f05a29e1,
title = "Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells",
abstract = "Aldosterone production occurs in the adrenal cortex, and is regulated primarily by angiotensin II (Ang II), potassium and adrenocorticotropin (ACTH). In the presence of the aldosterone stimulators, steroidogenesis is further governed by local autocrine and/or paracrine factors in the adrenal cortex. We reported the presence of functional bone morphogenetic protein (BMP) system in the adrenal cortex and also demonstrated that BMP-6 increases Ang Il-induced aldosterone production, which could be involved in the {"}aldosterone breakthrough{"} phenomenon. Aldosterone breakthrough is the phenomenon by which circulating aldosterone concentrations increase above pre-treatment levels after long-term therapy with ACE inhibitors or Ang II type 1 receptor antagonists (ARB). This phenomenon may lead to important clinical consequences since increased aldosterone in a high-salt state facilitates cardiovascular and renal damage in hypertensive patients. We found that long-term ARB treatment reverses the reduction of aldosterone synthesis by adrenocortical cells, thereby causing {"}cellular aldosterone breakthrough{"}. The availability of BMP-6 in the adrenal cortex may be at least partly involved in the occurrence of cellular escape from aldosterone suppression under chronic treatment with ARB.",
keywords = "Adrenal cortex, Aldosterone, Angiotensin II, Bone morphogenetic protein",
author = "Hiroyuki Otani and Fumio Otsuka and Kenichi Inagaki and Jiro Suzuki and Hirofumi Makino",
year = "2010",
month = "8",
language = "English",
volume = "64",
pages = "213--218",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells

AU - Otani, Hiroyuki

AU - Otsuka, Fumio

AU - Inagaki, Kenichi

AU - Suzuki, Jiro

AU - Makino, Hirofumi

PY - 2010/8

Y1 - 2010/8

N2 - Aldosterone production occurs in the adrenal cortex, and is regulated primarily by angiotensin II (Ang II), potassium and adrenocorticotropin (ACTH). In the presence of the aldosterone stimulators, steroidogenesis is further governed by local autocrine and/or paracrine factors in the adrenal cortex. We reported the presence of functional bone morphogenetic protein (BMP) system in the adrenal cortex and also demonstrated that BMP-6 increases Ang Il-induced aldosterone production, which could be involved in the "aldosterone breakthrough" phenomenon. Aldosterone breakthrough is the phenomenon by which circulating aldosterone concentrations increase above pre-treatment levels after long-term therapy with ACE inhibitors or Ang II type 1 receptor antagonists (ARB). This phenomenon may lead to important clinical consequences since increased aldosterone in a high-salt state facilitates cardiovascular and renal damage in hypertensive patients. We found that long-term ARB treatment reverses the reduction of aldosterone synthesis by adrenocortical cells, thereby causing "cellular aldosterone breakthrough". The availability of BMP-6 in the adrenal cortex may be at least partly involved in the occurrence of cellular escape from aldosterone suppression under chronic treatment with ARB.

AB - Aldosterone production occurs in the adrenal cortex, and is regulated primarily by angiotensin II (Ang II), potassium and adrenocorticotropin (ACTH). In the presence of the aldosterone stimulators, steroidogenesis is further governed by local autocrine and/or paracrine factors in the adrenal cortex. We reported the presence of functional bone morphogenetic protein (BMP) system in the adrenal cortex and also demonstrated that BMP-6 increases Ang Il-induced aldosterone production, which could be involved in the "aldosterone breakthrough" phenomenon. Aldosterone breakthrough is the phenomenon by which circulating aldosterone concentrations increase above pre-treatment levels after long-term therapy with ACE inhibitors or Ang II type 1 receptor antagonists (ARB). This phenomenon may lead to important clinical consequences since increased aldosterone in a high-salt state facilitates cardiovascular and renal damage in hypertensive patients. We found that long-term ARB treatment reverses the reduction of aldosterone synthesis by adrenocortical cells, thereby causing "cellular aldosterone breakthrough". The availability of BMP-6 in the adrenal cortex may be at least partly involved in the occurrence of cellular escape from aldosterone suppression under chronic treatment with ARB.

KW - Adrenal cortex

KW - Aldosterone

KW - Angiotensin II

KW - Bone morphogenetic protein

UR - http://www.scopus.com/inward/record.url?scp=77956631542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956631542&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 213

EP - 218

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -